<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02132572</url>
  </required_header>
  <id_info>
    <org_study_id>MAF-AGN-MED-BRE-003</org_study_id>
    <nct_id>NCT02132572</nct_id>
  </id_info>
  <brief_title>Retrospective Study of Incidence and Etiology of Reoperation After Primary Augmentation With Natrelle® Breast Implants</brief_title>
  <acronym>RANBI</acronym>
  <official_title>Retrospective Multi-centre, Post-marketing Study to Evaluate the Incidence and Aetiology of Reoperations With Allergan Natrelle® Breast Implants in Primary Augmentation (RANBI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective multi-center, post-marketing study to evaluate the incidence and etiology of
      reoperations with Allergan Natrelle® Breast Implants in primary augmentation (RANBI)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With First Reoperation Following Use of a BIOCELL™ Textured 410 Implant</measure>
    <time_frame>3 to 10 years</time_frame>
    <description>Data were retrospectively collected on the percentage of subjects who had a first reoperation following previous breast augmentation with a BIOCELL™ Textured 410 Implant.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">201</enrollment>
  <condition>Breast Implantation</condition>
  <arm_group>
    <arm_group_label>Natrelle BIOCELL™ Textured 410 Implant</arm_group_label>
    <description>Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIOCELL™ Textured 410 Implant</intervention_name>
    <description>Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.</description>
    <arm_group_label>Natrelle BIOCELL™ Textured 410 Implant</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects that have undergone a primary breast augmentation for aesthetic reasons with a
        Natrelle BIOCELL™ textured 410 cohesive implant
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary breast augmentation (either bilateral or unilateral) operated on by the
             investigating surgeon with an infra-mammary approach 410 cohesive BIOCELL™ textured
             device (Truform 2 &amp; 3 only) has been implanted

          -  Primary breast augmentation 3 to 10 years prior to data collection

          -  Submuscular/dual plane or subglandular implant placement

        Exclusion Criteria:

          -  Breast augmentation for Poland Syndrome or amastia

          -  Breast reconstruction following mastectomy

          -  Revision or secondary breast reconstruction

          -  Non 410 device at initial breast augmentation

          -  Women subsequently diagnosed with fibrocystic disease considered to be pre-malignant

          -  Procedures of the breast not related to the primary breast augmentation (e.g. excision
             of skin lesions)

          -  Axillary or peri-areolar approach

          -  Glandular mastopexy augmentation (skin excision only)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Grinstead</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2014</study_first_posted>
  <results_first_submitted>July 26, 2016</results_first_submitted>
  <results_first_submitted_qc>July 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 13, 2016</results_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Natrelle BIOCELL™ Textured 410 Implant</title>
          <description>Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Natrelle BIOCELL™ Textured 410 Implant</title>
          <description>Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>17 to 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 to 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41 to 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51 to 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61 to 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing age data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With First Reoperation Following Use of a BIOCELL™ Textured 410 Implant</title>
        <description>Data were retrospectively collected on the percentage of subjects who had a first reoperation following previous breast augmentation with a BIOCELL™ Textured 410 Implant.</description>
        <time_frame>3 to 10 years</time_frame>
        <population>Per Protocol: Subjects who underwent a primary breast augmentation with BIOCELL™ textured 410 cohesive breast implants 3 to 10 years prior to data collection</population>
        <group_list>
          <group group_id="O1">
            <title>Natrelle BIOCELL™ Textured 410 Implant</title>
            <description>Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With First Reoperation Following Use of a BIOCELL™ Textured 410 Implant</title>
          <description>Data were retrospectively collected on the percentage of subjects who had a first reoperation following previous breast augmentation with a BIOCELL™ Textured 410 Implant.</description>
          <population>Per Protocol: Subjects who underwent a primary breast augmentation with BIOCELL™ textured 410 cohesive breast implants 3 to 10 years prior to data collection</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population included all subject who underwent a primary breast augmentation with BIOCELL™ textured 410 cohesive breast implants for aesthetic reasons. The Safety Population was used to assess adverse events and serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Natrelle BIOCELL™ Textured 410 Implant</title>
          <description>Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device Breakage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Device Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Capsular Contracture Associated with Breast Implant</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Device Optical Issue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Device Damage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Device Deployment Issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Device Expulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Impaired Healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Implant Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Device Issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer Female</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Nipple Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Breast Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Scar Excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Medical Affairs,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

